US2022275419A1PendingUtilityA1
Method for the preparation of low molecular weight porcine lympho-reticular polypeptides and formulations thereof
Est. expiryAug 15, 2039(~13 yrs left)· nominal 20-yr term from priority
C12Y 304/22002C12N 9/50C12P 21/06C12Y 301/03008C07K 14/47C12Y 302/01001C12Y 304/23001
38
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
A method for preparation of low molecular weight porcine lympho-reticular polypeptides. The method comprises the enzymatic hydrolysis of a source of protein, wherein the source of protein comprises a blend of porcine liver and porcine spleen, with a first enzyme having proteolytic activity and a second enzyme having amylase activity.
Claims
exact text as granted — not AI-modified1 . (canceled)
2 . (canceled)
3 . (canceled)
4 . (canceled)
5 . (canceled)
6 . (canceled)
7 . (canceled)
8 . (canceled)
9 . (canceled)
10 . (canceled)
11 . (canceled)
12 . (canceled)
13 . (canceled)
14 . (canceled)
15 . (canceled)
16 . (canceled)
17 . A low molecular weight porcine lympho-reticular polypeptides formulation, comprising:
a low molecular weight porcine lympho-reticular polypeptide, a vitamin, an antioxidant, and zinc.
18 . The low molecular weight porcine lympho-reticular polypeptides formulation of claim 17 , wherein the antioxidant is alpha lipoic acid.
19 . The low molecular weight porcine lympho-reticular polypeptides formulation of claim 17 , wherein the antioxidant is selected from resveratrol, glutathione, quercetin or astaxanthin, or combinations thereof.
20 . The low molecular weight porcine lympho-reticular polypeptides formulation of claim 17 , wherein the zinc is zinc gluconate dihydrate or zinc glycinate chelate.
21 . The low molecular weight porcine lympho-reticular polypeptides formulation of claim 17 , wherein the vitamin is selected from vitamin C, vitamin D3, vitamin B1, vitamin B2, vitamin B3, vitamin B5, vitamin B6, vitamin B12, biotin, and folic acid, or combinations thereof.
22 . A low molecular weight porcine lympho-reticular polypeptides formulation, comprising:
low molecular weight porcine lympho-reticular polypeptide, a vitamin, bovine thymus extract, ascorbic acid, resveratrol, and zinc.
23 . The low molecular weight porcine lympho-reticular polypeptides formulation of claim 22 , wherein the vitamin is selected from vitamin C, vitamin D3, vitamin B1, vitamin B2, vitamin B3, vitamin B5, vitamin B6, vitamin B12, biotin, and folic acid, or combinations thereof.
24 . The low molecular weight porcine lympho-reticular polypeptides formulation of claim 22 , wherein the zinc is zinc gluconate dihydrate or zinc glycinate chelate.
25 . A low molecular weight porcine lympho-reticular polypeptides formulation, comprising:
a low molecular weight porcine lympho-reticular polypeptide, an antioxidant, alpha glycerylphophorylcholine, and zinc.
26 . The low molecular weight porcine lympho-reticular polypeptides formulation of claim 25 , wherein the antioxidant is alpha lipoic acid.
27 . The low molecular weight porcine lympho-reticular polypeptides formulation of claim 25 , wherein the antioxidant is selected from resveratrol, glutathione, quercetin or astaxanthin, or combinations thereof.
28 . The low molecular weight porcine lympho-reticular polypeptides formulation of claim 25 , wherein the zinc is zinc gluconate dihydrate or zinc glycinate chelate.
29 . A low molecular weight porcine lympho-reticular polypeptides formulation, comprising:
a low molecular weight porcine lympho-reticular polypeptide, a vitamin, ascorbic acid, and zinc.
30 . The low molecular weight porcine lympho-reticular polypeptides formulation of claim 29 , wherein the zinc is zinc gluconate dihydrate or zinc glycinate chelate.
31 . The low molecular weight porcine lympho-reticular polypeptides formulation of claim 30 , wherein the vitamin is selected from vitamin C, vitamin D3, vitamin B1, vitamin B2, vitamin B3, vitamin B5, vitamin B6, vitamin B12, biotin, and folic acid, or combinations thereof.
32 . A low molecular weight porcine lympho-reticular polypeptides formulation, comprising:
a low molecular weight porcine lympho-reticular polypeptide, chondroitin, an antioxidant, and glucosamine.
33 . The low molecular weight porcine lympho-reticular polypeptides formulation of claim 32 , wherein the antioxidant is alpha lipoic acid.
34 . The low molecular weight porcine lympho-reticular polypeptides formulation of claim 32 , wherein the antioxidant is selected from resveratrol, glutathione, quercetin or astaxanthin, or combinations thereof.
35 . A low molecular weight porcine lympho-reticular polypeptides formulation, comprising:
a low molecular weight porcine lympho-reticular polypeptide, an antioxidant, L-Carnitine, a vitamin, and magnesium chloride.
36 . The low molecular weight porcine lympho-reticular polypeptides formulation of claim 35 , wherein the antioxidant is alpha lipoic acid.
37 . The low molecular weight porcine lympho-reticular polypeptides formulation of claim 35 , wherein the antioxidant is selected from resveratrol, glutathione, quercetin or astaxanthin, or combinations thereof.
38 . The low molecular weight porcine lympho-reticular polypeptides formulation of claim 35 , wherein the vitamin is selected from vitamin C, vitamin D3, vitamin B1, vitamin B2, vitamin B3, vitamin B5, vitamin B6, vitamin B12, biotin and folic acid, or combinations thereof.
39 . (canceled)
40 . The low molecular weight porcine lympho-reticular polypeptides formulation of any of claim 32 , wherein the amino acid is L-Lysine.Join the waitlist — get patent alerts
Track US2022275419A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.